These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 26933761

  • 1. Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair.
    Harnicek D, Kampmann E, Lauber K, Hennel R, Cardoso Martins AS, Guo Y, Belka C, Mörtl S, Gallmeier E, Kanaar R, Mansmann U, Hucl T, Lindner LH, Hiddemann W, Issels RD.
    Int J Cancer; 2016 Jul 15; 139(2):467-79. PubMed ID: 26933761
    [Abstract] [Full Text] [Related]

  • 2. Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.
    García MJ, Saucedo-Cuevas LP, Muñoz-Repeto I, Fernández V, Robles MJ, Domingo S, Palacios J, Aracil M, Nieto A, Tercero JC, Benítez J.
    Mol Cancer Ther; 2013 Apr 15; 12(4):530-41. PubMed ID: 23364677
    [Abstract] [Full Text] [Related]

  • 3. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.
    Lima M, Bouzid H, Soares DG, Selle F, Morel C, Galmarini CM, Henriques JA, Larsen AK, Escargueil AE.
    Oncotarget; 2016 May 03; 7(18):25885-901. PubMed ID: 27029031
    [Abstract] [Full Text] [Related]

  • 4. Role of homologous recombination in trabectedin-induced DNA damage.
    Tavecchio M, Simone M, Erba E, Chiolo I, Liberi G, Foiani M, D'Incalci M, Damia G.
    Eur J Cancer; 2008 Mar 03; 44(4):609-18. PubMed ID: 18243687
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
    Monk BJ, Lorusso D, Italiano A, Kaye SB, Aracil M, Tanović A, D'Incalci M.
    Cancer Treat Rev; 2016 Nov 03; 50():175-182. PubMed ID: 27710871
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. BRCA2 protects mammalian cells from heat shock.
    Nakagawa Y, Kajihara A, Takahashi A, Murata AS, Matsubayashi M, Ito SS, Ota I, Nakagawa T, Hasegawa M, Kirita T, Ohnishi T, Mori E.
    Int J Hyperthermia; 2018 Sep 03; 34(6):795-801. PubMed ID: 28891354
    [Abstract] [Full Text] [Related]

  • 9. Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.
    Laroche A, Chaire V, Le Loarer F, Algéo MP, Rey C, Tran K, Lucchesi C, Italiano A.
    J Hematol Oncol; 2017 Apr 11; 10(1):84. PubMed ID: 28399901
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder.
    Rocca CJ, Soares DG, Bouzid H, Henriques JA, Larsen AK, Escargueil AE.
    Cell Cycle; 2015 Apr 11; 14(13):2080-90. PubMed ID: 25945522
    [Abstract] [Full Text] [Related]

  • 12. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA, Pirker C, Dong Y, Schelch K, Heffeter P, Kryeziu K, van Schoonhoven S, Klikovits T, Laszlo V, Rozsas A, Ozsvar J, Klepetko W, Döme B, Grusch M, Hegedüs B, Berger W.
    Mol Cancer Ther; 2016 Oct 11; 15(10):2357-2369. PubMed ID: 27512118
    [Abstract] [Full Text] [Related]

  • 13. Trabectedin is a promising antitumor agent potentially inducing melanocytic differentiation for clear cell sarcoma.
    Nakai T, Imura Y, Tamiya H, Yamada S, Nakai S, Yasuda N, Kaneko K, Outani H, Takenaka S, Hamada K, Myoui A, Araki N, Ueda T, Itoh K, Yoshikawa H, Naka N.
    Cancer Med; 2017 Sep 11; 6(9):2121-2130. PubMed ID: 28745431
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.
    Aune GJ, Takagi K, Sordet O, Guirouilh-Barbat J, Antony S, Bohr VA, Pommier Y.
    Clin Cancer Res; 2008 Oct 15; 14(20):6449-55. PubMed ID: 18927284
    [Abstract] [Full Text] [Related]

  • 16. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin.
    Casado JA, Río P, Marco E, García-Hernández V, Domingo A, Pérez L, Tercero JC, Vaquero JJ, Albella B, Gago F, Bueren JA.
    Mol Cancer Ther; 2008 May 15; 7(5):1309-18. PubMed ID: 18483318
    [Abstract] [Full Text] [Related]

  • 17. Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i.
    Oei AL, Ahire VR, van Leeuwen CM, Ten Cate R, Stalpers LJA, Crezee J, Kok HP, Franken NAP.
    Int J Hyperthermia; 2018 Feb 15; 34(1):39-48. PubMed ID: 28540821
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition.
    Guirouilh-Barbat J, Antony S, Pommier Y.
    Mol Cancer Ther; 2009 Jul 15; 8(7):2007-14. PubMed ID: 19584237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.